Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities

O’Neil, Serena; Lundbäck, Bo; Lötvall, Jan

doi:10.1016/j.jprot.2011.10.008

Cited by 34 publications

(28 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unidentified proteins may account for up to 60% of the total proteomic database and it is unclear exactly how large it is. 37,39 Mapping of the proteome is more advanced than the metabolome, however, with drafts of the human and lung proteomes available. 34 Crucially, as with metabolomics, the majority of reported proteomic findings have yet to be validated.…”

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

“…EBC, which has a low protein content, forms only a minority of the literature, whereas sputum, lung epithelial lining, or BAL fluid, which more directly reflect the lungs activity, are much more commonly used. 39 The abundance of proteins in plasma and serum can be both an advantage and a disadvantage, particularly for the measurement of the less abundant, lower molecular weight proteins. 41 The choice of biospecimen may therefore affect the findings 34 and is an important consideration for integrated omics moving forward.…”

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Kelly

Dahlin

McGeachie

et al. 2017

Chest

149

135

View full text Add to dashboard Cite

Asthma is a complex disease well-suited to metabolomic profiling, both for the development of novel biomarkers and for the improved understanding of pathophysiology. In this review, we summarize the 21 existing metabolomic studies of asthma in humans, all of which reported significant findings and concluded that individual metabolites and metabolomic profiles measured in exhaled breath condensate, urine, plasma, and serum could identify people with asthma and asthma phenotypes with high discriminatory ability. There was considerable consistency across the studies in terms of the reported biomarkers, regardless of biospecimen, profiling technology, and population age. In particular, acetate, adenosine, alanine, hippurate, succinate, threonine, and trans-aconitate, and pathways relating to hypoxia response, oxidative stress, immunity, inflammation, lipid metabolism and the tricarboxylic acid cycle were all identified as significant in at least two studies. There were also a number of nonreplicated results; however, the literature is not yet sufficiently developed to determine whether these represent spurious findings or reflect the substantial heterogeneity and limited statistical power in the studies and their methods to date. This review highlights the need for additional asthma metabolomic studies to explore these issues, and, further, the need for standardized methods in the way these studies are conducted. We conclude by discussing the potential of translation of these metabolomic findings into clinically useful biomarkers and the crucial role that integrated omics is likely to play in this endeavor.CHEST 2017; 151(2):262-277

show abstract

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

Section: Biological Insights Into Asthma Pathophysiology and Treatmentmentioning

confidence: 99%

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Kelly

Dahlin

McGeachie

et al. 2017

Chest

149

135

View full text Add to dashboard Cite

show abstract

“…Here, the authors increased proteome coverage through depletion of the top 14 most abundant proteins, identifying 113 low abundance proteins, 16 of which were differentially expressed between smokers and nonsmokers. The iTRAQ approach, coupled with nano-LC-LTQ-Orbitrap, has also been used to compare the proteomes of bronchial biopsy samples from healthy and asthmatic subjects and to identify differences in response to glucocorticoid treatment [73]. An extensive number of proteins were identified despite limited material for analysis and lack of abundant protein depletion.…”

Section: Proteomicsmentioning

confidence: 99%

Application of ’omics technologies to biomarker discovery in inflammatory lung diseases

et al. 2013

View full text Add to dashboard Cite

Inflammatory lung diseases are highly complex in respect of pathogenesis and relationships between inflammation, clinical disease and response to treatment. Sophisticated large-scale analytical methods to quantify gene expression (transcriptomics), proteins (proteomics), lipids (lipidomics) and metabolites (metabolomics) in the lungs, blood and urine are now available to identify biomarkers that define disease in terms of combined clinical, physiological and patho-biological abnormalities. The aspiration is that these approaches will improve diagnosis, i.e. define pathological phenotypes, and facilitate the monitoring of disease and therapy, and also, unravel underlying molecular pathways. Biomarker studies can either select predefined biomarker(s) measured by specific methods or apply an ''unbiased'' approach involving detection platforms that are indiscriminate in focus. This article reviews the technologies presently available to study biomarkers of lung disease within the 'omics field. The contributions of the individual 'omics analytical platforms to the field of respiratory diseases are summarised, with the goal of providing background on their respective abilities to contribute to systems medicine-based studies of lung disease. @ERSpublications Summary of the application of 'omics-based analytical platforms for biomarker discovery in inflammatory lung diseases

show abstract

“…The complexity of the disease combined with the inaccessibility and invasiveness of disease relevant samples have provided a hurdle to the progress of respiratory proteomics. Advances in proteomic instrumentation and methodology have led to the possibility of identifying proteomes in much smaller quantities of biologic material 40 . This is likely to contribute to the increased understanding of the disease mechanism, establishment of biomarkers for these endotypes and improved patient care.…”

Section: Biomarkersmentioning

confidence: 99%

Respiratory muscle assessment in acute exacerbation of chronic obstructive pulmonary disease and its role as a potential biomarker

Vimal¹,

Kolek²,

Jaskova³

2012

BIOMED PAP

View full text Add to dashboard Cite

Background. AECOPD is a life threatening condition for patients with chronic obstructive pulmonary disease (COPD) and lack of specific biomarker hinders effective management. Sputum, blood, breath and urinary biomarkers have all been investigated. We measured maximum respiratory pressure post exacerbation once the patient was compliant with the test and after 6 weeks, to assess any correlations. Methods and Results. The maximum pressures were measured using a closed circuit spirometer with a clean rubber mouthpiece properly placed with the patients lips sealed around it. Patients were properly instructed to exhale slowly and completely, then inspire with maximum possible effort and advised to keep it for nearly 1.5 s for maximum inspiratory pressure (MIP). For maximum expiratory pressures (MEP) patients were instructed to inspire slowly and completely, then expire forcefully with maximum effort. With the recorded values TTI (time tension index) was calculated. This was repeated again after 6 weeks. Using Pearsons correlation coefficient we found that MIP had a negative correlation with TTI and a positive correlation with FEV1. FEV1 had a positive correlation with FVC. MEP showed no significant correlation with TTI, but a positive correlation with FEV1. Conclusion. Acute exacerbations of COPD has a profound effect on the respiratory musculature especially the expiratory muscles but the maximum pressures are not specific enough to be prognostic markers. It might be worthwhile studying transformations of the respiratory musculature at the molecular level. More studies must be conducted to find a specific marker to aid in the management of the condition.

show abstract

Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities

Cited by 34 publications

References 103 publications

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic

Application of ’omics technologies to biomarker discovery in inflammatory lung diseases

Respiratory muscle assessment in acute exacerbation of chronic obstructive pulmonary disease and its role as a potential biomarker

Contact Info

Product

Resources

About